Evidence map›Paper›PMID 27755169›Full record

ReviewCurrent opinion in organ transplantation2016

Emerging advancements in liver regeneration and organogenesis as tools for liver replacement.

Stacey S Huppert, Kathleen M Campbell

Abstract readReview
In one paragraph

Review in Current opinion in organ transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Molecular regulation of mammalian hepatic architecture.Current topics in developmental biology · 2019
    Review
  7. Review
  8. Review
  9. Clinical Hepatocyte Transplantation: What Is Next?Current transplantation reports · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Stacey S HuppertaDivision of Gastroenterology, Hepatology and Nutrition bDivision of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Kathleen M Campbell
Cincinnati Children's Hospital Medical Center · US

Funding

Building a functional biliary system from hepatocytesR01DK107553 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI HUPPERT, STACEY S, WILLENBRING, HOLGER · 2016 to 2020
$2.4M
Molecular requirements for proliferation of fetal and adult liver progenitorsR01DK078640 · NIDDK · VANDERBILT UNIVERSITY · PI HUPPERT, STACEY S · 2008 to 2012
$1.5M
NIDDK NIH HHS R01 DK078640NIDDK NIH HHS R01 DK107553
6 · The paper itself

Abstract

purpose of reviewAlthough the liver possesses a unique, innate ability to regenerate through mass compensation, transplantation remains the only therapy when damage outpaces regeneration, or liver metabolic capacity is irreversibly impacted. Recent insight from developmental biology has greatly influenced the advancement of alternative options to transplantation in these settings. RECENT

findingsFactors known to direct liver cell specification, expansion, and differentiation have been used to generate hepatocyte-like cells from stem and somatic cells for developing cell therapies. Additionally, interactions between hepatic epithelial and nonepithelial cells key to establishing hepatic architecture have been used in tissue engineering approaches to advance self-organizing hepatic organoids and bioartificial liver devices. Simultaneously, recent clinically applicable advances in human hepatocyte transplantation and promotion of innate hepatic regeneration have been limited. SUMMARY: Although mature hepatocytes have the potential to bridge to, or replace whole organ transplantation, limits in the ability to obtain healthy cells, stabilize in-vitro expansion, cryopreserve, and alleviate rejection, still exist. Alternative sources for generating hepatocytes hold promise for cell therapy and tissue engineering. These may allow generation of autologous or universal donor cells that eliminate the need for immunosuppression; however, limits exist regarding hepatocyte maturity and efficacy at liver repopulation, as well as applicability to human chronic liver disease.

Indexed as

Liver RegenerationOrganogenesisTissue EngineeringAnimalsHepatocytesHumansLiverLiver, ArtificialLiver Diseases

Identifiers

PMID27755169
PMCPMC5439303
OpenAlexW2530426952

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.